摘要
肝癌是目前最常见的原发性肝脏恶性肿瘤,据统计数据显示,我国每年有30万例以上患者死于肝癌,约占全世界肝癌死亡总例数的50%。肝移植是治疗肝癌的重要手段之一,然而,术后肝癌复发转移影响着患者的长期生存状况。肝癌肝移植术后使用预后评分模型评估复发风险,对受者规律随访、密切监测,制定个体化、低剂量、联合用药的免疫抑制方案,规范抗病毒治疗均有益于降低复发风险。一旦明确复发转移,综合手术切除、局部治疗以及系统治疗的综合性治疗有助于控制疾病进展,延长生存时间。本文聚焦肝癌肝移植术后肿瘤复发转移的防治新进展,以期为未来临床实践和科研探索提供参考和借鉴。
Hepatocellular carcinoma(HCC)is currently the most common primary malignant tumor of liver.According to the statistic data,more than 300000 patients die of HCC in China each year,accounting for approximately 50%of the total number of HCC deaths worldwide.Liver transplantation is one of the important methods for treating HCC.However,postoperative recurrence and metastasis of HCC affect the long-term survival of patients.The use of prognostic scoring models to assess the risk of recurrence after liver transplantation for HCC,regular follow-up and close monitoring of recipients,individualized,low-dose and combined immunosuppressive regimens and standardized antiviral therapy are all beneficial for reducing the risk of recurrence.Once recurrence and metastasis are confirmed,comprehensive treatment combining surgical resection,local treatment and systemic treatment is helpful in controlling disease progression and prolonging survival time.This article focuses on the new progress in the prevention and treatment of tumor recurrence and metastasis after liver transplantation for HCC,with the aim of providing reference and inspiration for future clinical practice and scientific research.
作者
李文磊
栗光明
Li Wenlei;Li Guangming(General Surgery Center,Beijing You'an Hospital,Capital Medical University,Beijing 100069,China)
出处
《器官移植》
北大核心
2025年第2期208-213,共6页
Organ Transplantation
基金
国家科技重大专项(2023ZD0502405)。
关键词
肝癌
肝移植
复发
转移
免疫抑制
肿瘤预后
甲胎蛋白
乙型病毒性肝炎
Hepatocellular carcinoma
Liver transplantation
Recurrence
Metastasis
Immunosuppression
Tumor prognosis
Alpha-fetoprotein
Hepatitis B virus
